Medicare Research Priorities: A Taste Of What's To Come?
This article was originally published in RPM Report
Executive Summary
Any government-sponsored center on comparative effectiveness will focus on the research priorities of the Medicare and Medicaid programs as a way to lower health care costs. The findings of a Medicare coverage advisory committee offers a glimpse of where those priorities may fall.
You may also be interested in...
The Devil is in the Details: CMS To Flesh Out Committee's Research Role
CMS plans to be more open about how the Medicare coverage advisory committee will score research priorities after comments from industry. Stakeholders know the process won't any easier after Election Day.
The Value Proposition: Why Pharma Should Embrace Comparative Effectiveness
A greater investment in comparative effectiveness research appears inevitable, whether or not Congress creates a federally funded agency to conduct head-to-head trials. The Vytorin debacle is only the most recent reason why industry is wary. But there are steps pharma can take to prepare for the next big thing in health care policy. Despite Vytorin, Merck is one of the companies leading the way.
Show Me the Value
As cancer drug prices approach $100,000, manufacturers are facing strong resistance from manufacturers. Now Wall Street is starting to worry.